Merck announces filing of form 10 registration statement in connection with planned spinoff of Organon & Co..

Merck announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission (“SEC”) in connection with the intended spinoff of its women’s health, biosimilars and established brands businesses into a standalone, publicly-traded company, Organon.If all conditions are met, the separation is on track for completion late in the second quarter of 2021. Organon will be a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. It will have a portfolio of more than 60 trusted medicines that address an entire spectrum of conditions women face and other medical needs. Led by the growing reproductive health portfolio including patent-protected Nexplanon (etonogestrel implant), coupled with an expanding biosimilars business and stable franchise of established medicines.